Soluble glycoprotein v for treating thrombotic diseases
AssigneeJulius-Maximilians-UniversitäT WüRzburg
InventorsBernhard NIESWANDT, Sarah BECK, David STEGNER
Life of this patent
Estimating the term…
Abstract
A soluble polypeptide comprising a modified glycoprotein V (GPV) lacking a functional transmembrane domain for use in the treatment or prevention of a thrombotic disease in a subject, said treatment or prevention comprising administering to the subject an effective amount of said soluble polypeptide.
Claims23
A method for the treatment and/or prevention of a thrombotic disease in a subject, comprising administering to the subject an effective amount of a soluble polypeptide comprising a modified glycoprotein V (GPV) lacking a functional transmembrane domain.
A pharmaceutical composition comprising a soluble polypeptide comprising a modified GPV lacking a functional transmembrane domain, and a pharmaceutically acceptable excipient.
A method of preparing a soluble polypeptide, comprising expressing a nucleic acid encoding the soluble polypeptide in a mammalian cell, culturing the mammalian cell in a culture medium, and recovering the soluble polypeptide from the culture medium, wherein the soluble polypeptide comprises a modified GPV lacking a functional transmembrane domain.
A non-naturally occurring soluble GPV lacking a functional transmembrane domain.
A soluble GPV lacking a functional transmembrane domain, wherein the soluble GPV does not consist of the amino acid sequence of SEQ ID NO:10.
A pharmaceutical kit comprising (i) a soluble polypeptide comprising a modified GPV lacking a functional transmembrane domain, and (ii) an anti-platelet or an anti-coagulant drug other than the soluble polypeptide.
Dependencies are inferred from the claim text.